Literature DB >> 29797786

Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System.

Sowmya Balasubramanian1, Robert B Peery2, Jeremy Minshull3, Maggie Lee3, Regina White2, Ronan M Kelly1, Gavin C Barnard2.   

Abstract

Clonally derived cell lines (CDCL) from Chinese Hamster Ovary (CHO) host cell lines, remain the most popular method to manufacture therapeutic proteins. However, CHO cell pools are increasingly being used as an alternate method to produce therapeutic proteins for preclinical drug development in an effort to shorten the time required for new drug development. It is essential that these CHO pools exhibit the desired attributes of CHO CDCLs such as high protein titers and consistent product quality attributes (PQAs). In this study the authors evaluated the Leap-In Transposase®, for the expression of four different proteins (three mAbs and one Bispecific mAb). The resultant pool titers ranges from 2.0 to 5.0 g L-1 for the four proteins compared to 1.5-3.3 g L-1 from the respective control pools (generated by random gene integration). The resultant cell pools are a homogeneously expressing cell population. The average gene copy numbers are similar or lower in the evaluation pools relative to the control pools. The higher titers in the evaluation pools are attributed to higher levels of both IgG-LC and IgG-HC mRNA. In conclusion, the Leap-In transposase generates high titer, homogeneous CHO pools in a short time-period without introducing any undesired PQAs.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CHO pools; Leap-In; antibody production; recombinant protein; transposon

Mesh:

Substances:

Year:  2018        PMID: 29797786     DOI: 10.1002/biot.201700748

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  2 in total

Review 1.  Development of bispecific antibodies in China: overview and prospects.

Authors:  Jing Zhang; Jizu Yi; Pengfei Zhou
Journal:  Antib Ther       Date:  2020-05-30

2.  Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines.

Authors:  Sowmya Rajendran; Sowmya Balasubramanian; Lynn Webster; Maggie Lee; Divya Vavilala; Nicolay Kulikov; Jessica Choi; Calvin Tang; Molly Hunter; Rebecca Wang; Harpreet Kaur; Surya Karunakaran; Varsha Sitaraman; Jeremy Minshull; Ferenc Boldog
Journal:  Biotechnol Bioeng       Date:  2021-04-02       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.